The role of plasmacytoid dendritic cells in ocular angiogenesis
浆细胞样树突状细胞在眼血管生成中的作用
基本信息
- 批准号:9893891
- 负责人:
- 金额:$ 49.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive Cell TransfersAdoptive TransferAffectAgonistArteriosclerosisBlood VesselsBlood capillariesBone MarrowCell ProliferationCell physiologyCellsChoroidal NeovascularizationCoculture TechniquesCorneaCorneal NeovascularizationDataDendritic CellsDichloromethylene DiphosphonateDiseaseEffectivenessEndostatinsEndothelial CellsEnzyme-Linked Immunosorbent AssayEquilibriumExhibitsExtracellular MatrixGrowth FactorHerpesvirus 1HumanImmuneImmunofluorescence ImmunologicIn VitroInflammationInflammatoryKeratitisLasersLinkLymphangiogenesisMaintenanceMalignant NeoplasmsMeasuresMediatingMessenger RNAMethodsMicroscopyModelingMolecularMorphologyMusMyocardial InfarctionNerveOxygenParticipantPathologicPathologic NeovascularizationPeptide HydrolasesPeptidesPlayProcessProductionPropertyProteinsQuantitative Reverse Transcriptase PCRRegulationRetinaRetinal DiseasesRetinal NeovascularizationRoleSimplexvirusSourceStainsStrokeStructure of trigeminal ganglionTLR7 geneTLR9 geneTimeTissue TransplantationTissuesToll-like receptorsTubeVascular Endothelial Celladaptive immune responseangiogenesisattenuationchemokinechronic woundclinically relevantdensityexperimental studyganglion cellin vivolimb ischemiamacrophagemigrationmonocytemulti-photonneovascularneovascularizationnovel therapeuticsocular angiogenesispreservationpreventsmall moleculetranscriptometumor
项目摘要
Project Summary
Angiogenesis is precisely regulated by a balance of growth factors, chemokines, proteases, and inflammatory
cells. Macrophages, monocytes, and conventional dendritic cells (cDCs) are involved in all stages of
angiogenesis from degradation of local extracellular matrix to proliferation of endothelial cells and capillary
formation. Despite the well-studied functions of these cells in angiogenesis, the role and source of endogenous
anti-angiogenic molecules which preserve corneal angiogenic privilege or prevent retinal neovascularization is
elusive. Moreover, the impact of recently identified plasmacytoid dendritic cells (pDCs), a vital subset of
immune cells that reside in the cornea and retina, remains to be determined. These cells orchestrate and link
innate and adaptive immune responses and are implicated in the induction of tolerance to transplanted tissues
or tumors. Our preliminary experiments showed that depletion of pDCs is accompanied by abrupt and severe
breakdown of angiogenic privilege of cornea and corneal pDCs co-stain with Endostatin, a well-known anti-
angiogenic molecule. We hypothesize that pDCs exhibit anti-angiogenic functions by actively secreting anti-
angiogenic molecules and are necessary for preserving corneal angiogenic privilege as well as limiting retinal
neovascularization in pathologic conditions. Our aims include identification of pro- and anti-angiogenic
molecules expressed by pDCs and their functional relevance on corneal angiogenic privilege, characterizing
the impact of pDCs on the avascular state of the cornea in steady-state and during inflammation, describing
the molecular and cellular participants involved in pDC-mediated inhibition of corneal angiogenesis during
neovascularization, and assessing how activation of pDCs through activation of toll like receptors (TLR)-7 and
TLR-9 via their synthetic agonists as well as Herpes Simplex Virus, their natural activator, affects
angiogenesis. Further, we aim to assess the impact of pDCs in preventing oxygen- as well as laser-induced
choroidal neovascularization and study the effectiveness of adoptive transfer of pDCs for treatment of retinal
neovascularization in these conditions. The application proposes a paradigm shift in our understanding of the
regulation of angiogenesis and corneal vascular privilege. Our fresh perspective on how pDCs contribute to
avascular state of cornea and restrict retinal neovascularization has applications beyond ocular tissues. It
would potentially introduce new therapeutic avenues in various pathologic conditions in which attenuation of
angiogenesis would be potentially beneficial such as cancers and inflammatory diseases, as well as in
conditions which induction of angiogenesis is advantageous, particularly in ischemic conditions.
项目摘要
血管生成受到生长因子、趋化因子、蛋白水解酶和炎症的精确调节。
细胞。巨噬细胞、单核细胞和常规树突状细胞(CDCs)参与了所有阶段的
从局部细胞外基质降解到内皮细胞和毛细血管增殖的血管生成
队形。尽管这些细胞在血管生成中的功能已经研究得很好,但内源性的作用和来源
维持角膜血管生成特权或防止视网膜新生血管的抗血管生成分子
难以捉摸。此外,最近发现的浆细胞样树突状细胞(PDCs)的影响,一个重要的亚群
驻留在角膜和视网膜中的免疫细胞仍有待确定。这些细胞协调和连接
先天和获得性免疫反应与诱导移植组织耐受有关
或者肿瘤。我们的初步实验表明,pDC的枯竭伴随着突然和严重的
内皮抑素对角膜和角膜PDCs血管生成特权的破坏作用
血管生成分子。我们推测PDCs通过主动分泌抗血管生成因子发挥抗血管生成功能。
血管生成分子,是保持角膜血管生成特权和限制视网膜所必需的
病理条件下的新生血管。我们的目标包括鉴定促血管生成和抗血管生成
PDCs表达的分子及其在角膜血管生成特权中的功能相关性
描述了PDCs在稳态和炎症期间对角膜无血管状态的影响
PDC抑制角膜新生血管形成的分子和细胞机制
新生血管形成,并评估pDC如何通过激活Toll样受体(TLR)-7和
TLR-9通过它们的合成激动剂以及它们的天然激活剂单纯疱疹病毒影响
血管生成。此外,我们的目标是评估PDCs在防止氧气和激光诱导方面的影响。
脉络膜新生血管及PDCs过继移植治疗视网膜的疗效研究
在这些条件下的新生血管。这个应用程序提出了我们对
血管生成的调节和角膜血管特权。我们对pdc如何做出贡献的新视角
角膜的无血管状态和限制视网膜新生血管的应用超出了眼组织。它
可能会在各种病理条件下引入新的治疗途径,在这些条件下,
血管生成可能是有益的,例如癌症和炎症性疾病,以及
诱导血管生成是有利的条件,特别是在缺血条件下。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pedram Hamrah其他文献
Pedram Hamrah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pedram Hamrah', 18)}}的其他基金
The role of plasmacytoid dendritic cells in corneal immunity
浆细胞样树突状细胞在角膜免疫中的作用
- 批准号:
10640026 - 财政年份:2023
- 资助金额:
$ 49.56万 - 项目类别:
Central and Peripheral Mechanisms of Corneal Pain
角膜疼痛的中枢和外周机制
- 批准号:
10707313 - 财政年份:2022
- 资助金额:
$ 49.56万 - 项目类别:
Central and Peripheral Mechanisms of Corneal Pain
角膜疼痛的中枢和外周机制
- 批准号:
10595408 - 财政年份:2022
- 资助金额:
$ 49.56万 - 项目类别:
Discovery of the Biomarker Signature for Neuropathic Corneal Pain
神经性角膜疼痛生物标志物特征的发现
- 批准号:
10617101 - 财政年份:2019
- 资助金额:
$ 49.56万 - 项目类别:
The role of plasmacytoid dendritic cells in ocular angiogenesis
浆细胞样树突状细胞在眼血管生成中的作用
- 批准号:
9318784 - 财政年份:2017
- 资助金额:
$ 49.56万 - 项目类别:
Role of plasmacytoid dendritic cells in corneal nerve health and regeneration
浆细胞样树突状细胞在角膜神经健康和再生中的作用
- 批准号:
9208776 - 财政年份:2016
- 资助金额:
$ 49.56万 - 项目类别:
The role of plasmacytoid dendritic cells in corneal immunity
浆细胞样树突状细胞在角膜免疫中的作用
- 批准号:
9329957 - 财政年份:2016
- 资助金额:
$ 49.56万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 49.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 49.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 49.56万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 49.56万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 49.56万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 49.56万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 49.56万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 49.56万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 49.56万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 49.56万 - 项目类别:














{{item.name}}会员




